Overview
Catherine has been part of the diabetes research team, led by Prof Andrew Hattersley since 2010, working on clinical research projects in diabetes, including genetics of diabetes and most recently stratification of Type 2.
She is currently manages the TriMaster clinical trial, a randomised double-blind three-way crossover trial of third-line diabetes therapies which aims to improve diabetes care by identifying groups of patients who may respond better to certain diabetes treatments. She is also involved in the NIHR Global Health project working to improve diabetes diagnosis and treatment in sub-Saharan Africa in collaboration with partners in Uganda and Cameroon.
Alongside these role she is a part-time PGR student looking at stratified medicine and treatment hetergeneity in Type 2 Diabetes.
Catherine is based in the NIHR Exeter Clinical Research Facility and UEMS Medical School. Previous studies include the MASTERMIND and RetroMASTER clinical studies, work with the Stroke Research Network for the INTERSTROKE study and the EU IMI-DIRECT and FP7-CEED3 projects.
Qualifications
MSc International Development (University of Bristol)
Research group links
Research
Research interests
Catherine's work is largely in clinical trials and research projects linked to stratification of Type 2 diabetes.
Research projects
- MRC-ABPI Stratification and Extreme Response Mechanism IN Diabetes (MASTERMIND), including MASTERMIND and RetroMASTER clinical studies
- NIHR Global Health: Improving outcomes in sub-Saharan African diabetes through better diagnosis and treatment
- Diabetes Research on Patient Stratification (DIRECT)
Previous projects:
- INTERSTROKE study - A study of the Importance of Conventional and Emerging Risk Factors of Stroke
- Collaborative European Effort to Develop Diabetes Diagnostics (CEED3)
Publications
Key publications | Publications by category | Publications by year
Publications by category
Journal articles
Angwin C, Pearson E, Hattersley A (2016). Crossover studies can help the individualisation of care in type 2 diabetes: the MASTERMIND approach.
Practical Diabetes,
33(4), 115-117.
Full text.
Conferences
Shakweh EY, Shields BM, Angwin CD, Rodgers LR, McDonald TJ, Pearson ER, Hattersley AT, Jones AG, Consortium M (2018). Precision medicine in Type 2 diabetes: is variation in response to sitagliptin and gliclazide therapy related to drug levels?.
Author URL.
Grubb AL, Patel KA, Oram RA, Hill AV, Angwin C, McDonald TJ, Weedon MN, Hattersley AT, Shields BV, Jones AG, et al (2017). Development of a risk calculator to identify patients with Type 1 diabetes who will require early insulin therapy.
Author URL.
Jones AG, Angwin C, Hammersley S, Rogers L, Shields BM, Pearson ER, Hattersley AT (2016). The DPPIV inhibitor sitagliptin lowers postprandial glucose without improving postprandial insulin secretion: a MASTERMIND study.
Author URL.
Dennis JM, Hattersley AT, Weedon M, Angwin C, Rodgers L, Pearson ER, Henley WE, Shields BM (2015). Development of oedema is associated with an improved glycaemic response in patients initiating thiazolidinediones: a MASTERMIND study.
Author URL.
Full text.
Dennis JM, Hattersley AT, Weedon M, Angwin CD, Rodgers L, Pearson ER, Henley WE, Shields BM (2015). Patients who develop oedema on initiating thiazolidinedione therapy have an improved glycaemic response: a MASTERMIND study.
Author URL.
Full text.
Rodgers LR, Pearson ER, Hammersley S, Angwin CD, JMcDonald T, Shields BM, Hattersley AT, Jones AG, Consortium MASTERMIND (2015). Patients with a high fasting glucose respond better to sulphonylureas than dipeptidyl peptidase IV (DPP-IV) inhibitors: a MASTERMIND study.
Author URL.
Rodgers LR, Pearson ER, Angwin CD, Hammersley S, McDonald TJ, Shields BM, Hattersley AT, Jones AG, Consortium M (2015). Response to glucose lowering therapy can be assessed by a brief period of treatment withdrawal: a MASTERMIND study.
Author URL.
Publications by year
2018
Shakweh EY, Shields BM, Angwin CD, Rodgers LR, McDonald TJ, Pearson ER, Hattersley AT, Jones AG, Consortium M (2018). Precision medicine in Type 2 diabetes: is variation in response to sitagliptin and gliclazide therapy related to drug levels?.
Author URL.
2017
Grubb AL, Patel KA, Oram RA, Hill AV, Angwin C, McDonald TJ, Weedon MN, Hattersley AT, Shields BV, Jones AG, et al (2017). Development of a risk calculator to identify patients with Type 1 diabetes who will require early insulin therapy.
Author URL.
2016
Angwin C, Pearson E, Hattersley A (2016). Crossover studies can help the individualisation of care in type 2 diabetes: the MASTERMIND approach.
Practical Diabetes,
33(4), 115-117.
Full text.
Jones AG, Angwin C, Hammersley S, Rogers L, Shields BM, Pearson ER, Hattersley AT (2016). The DPPIV inhibitor sitagliptin lowers postprandial glucose without improving postprandial insulin secretion: a MASTERMIND study.
Author URL.
2015
Dennis JM, Hattersley AT, Weedon M, Angwin C, Rodgers L, Pearson ER, Henley WE, Shields BM (2015). Development of oedema is associated with an improved glycaemic response in patients initiating thiazolidinediones: a MASTERMIND study.
Author URL.
Full text.
Dennis JM, Hattersley AT, Weedon M, Angwin CD, Rodgers L, Pearson ER, Henley WE, Shields BM (2015). Patients who develop oedema on initiating thiazolidinedione therapy have an improved glycaemic response: a MASTERMIND study.
Author URL.
Full text.
Rodgers LR, Pearson ER, Hammersley S, Angwin CD, JMcDonald T, Shields BM, Hattersley AT, Jones AG, Consortium MASTERMIND (2015). Patients with a high fasting glucose respond better to sulphonylureas than dipeptidyl peptidase IV (DPP-IV) inhibitors: a MASTERMIND study.
Author URL.
Rodgers LR, Pearson ER, Angwin CD, Hammersley S, McDonald TJ, Shields BM, Hattersley AT, Jones AG, Consortium M (2015). Response to glucose lowering therapy can be assessed by a brief period of treatment withdrawal: a MASTERMIND study.
Author URL.
Refresh publications
